Mallinckrodt plc Ordinary Shares (MNK): Price and Financial Metrics

Mallinckrodt plc Ordinary Shares (MNK): $0.75

-0.34 (-31.19%)

POWR Rating

Component Grades













MNK Stock Price Chart Interactive Chart >

Price chart for MNK

MNK Price/Volume Stats

Current price $0.75 52-week high $6.42
Prev. close $1.09 52-week low $0.75
Day low $0.75 Volume 16,890,200
Day high $1.00 Avg. volume 6,488,121
50-day MA $1.36 Dividend yield N/A
200-day MA $2.79 Market Cap 63.44M

Mallinckrodt plc Ordinary Shares (MNK) Company Bio

Mallinckrodt Public Limited Company is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology, neonatal critical care respiratory therapies, and analgesics and central nervous system drugs. The company was founded in 2013 and is based in Dublin, Ireland.

MNK Latest News Stream

Event/Time News Detail
Loading, please wait...

MNK Latest Social Stream

Loading social stream, please wait...

View Full MNK Social Stream

Latest MNK News From Around the Web

Below are the latest news stories about Mallinckrodt plc that investors may wish to consider to help them evaluate MNK as an investment opportunity.

Mallinckrodt: It's Your Move

A bird in the hand is worth two in the bush. - J. Capgrave "WSJ is controlled by shorties", "This is another trick to trick retail investors to give up their shares" and "#FakeNews". The recent WSJ article has incited vehement comments among stolid Mallinckrodt (MNK) investors, mostly criticizing and...

Zheng Feng Chee on Seeking Alpha | October 2, 2020

B. Braun Medical Inc. announces that it has previously settled its Hatch-Waxman litigation brought by Mallinckrodt

BETHLEHEM, Pa., Oct. 2, 2020 /PRNewswire/ -- B. Braun Medical Inc. announces that it has previously settled a patent infringement litigation brought by Mallinckrodt Hospital Products Inc., its affiliates, and New Pharmatop L.P. in response to B. Braun's new drug application (NDA) seeking…

PR Newswire | October 2, 2020

STAT Plus: ‘Are you an American, sir?’: Lawmakers interrogate Amgen, Novartis, Mallinckrodt executives on why U.S. prices are so high

“If you love this country, if you love America, you should be willing to tell Americans that they shouldn't be paying more than the French, and the Germans, and Europeans,”…

STAT News | October 1, 2020

Nuclear Medicine/Radiopharmaceutic Market Research With Size, Growth, Key Players, Segments And Forecasts Analysis 2020-2026(Bracco Imaging, Mallinckrodt, Lantheus Medical Imaging)

Los Angeles, United State, – – QY Research recently added a research report, Global Nuclear Medicine/Radiopharmaceutic Market Research Report 2020 to its ever-increasing repository. The research report discusses the future of the global Nuclear Medicine/Radiopharmaceutic market. It highlights the drivers

OpenPR | September 30, 2020

Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates

September proved to be a mixed month as far as drug approvals are concerned, with Mallinckrodt PLC (NYSE: MNK ) and Aquestive Therapeutics Inc (NASDAQ: AQST ) facing rejections. PDUFA dates are binary events that invariably serve as make-or-break catalysts for stocks. These dates are deadlines by which the FDA reviews a new drug application before announcing its decision concerning the approvability/non-approvability of the drug. Among the more fortunate ones were GlaxoSmithKline plc (NYSE: GSK ), which got the nod for an expanded indication - hypereosinophilic syndrome. Bristol-Myers Squibb Co's (NYSE: BMY ) leukemia drug also received FDA's blessings, and after several hiccups, Eton Pharmaceuticals Inc's (NASDAQ: ETON ) out-licensed preservative-free allergic conjunctivitis ophthalmic...

Benzinga | September 30, 2020

Read More 'MNK' Stories Here

MNK Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year -81.66%
5-year -97.90%
2021 N/A
2020 0.00%
2019 -77.91%
2018 -29.96%
2017 -54.72%

Continue Researching MNK

Want to see what other sources are saying about Mallinckrodt plc's financials and stock price? Try the links below:

Mallinckrodt plc (MNK) Stock Price | Nasdaq
Mallinckrodt plc (MNK) Stock Quote, History and News - Yahoo Finance
Mallinckrodt plc (MNK) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4164 seconds.